Healthcare / Medical Care FacilitiesNasdaqCM
$12.04
-0.87 (-6.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-91.2M · quality 75.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
95.3%
↑Gross Margin
N/A
•Debt/Equity
-1.84
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+46.9%
FCF CAGR
—
FCF margin
-6.3%
FCF / Net income
0.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.46B · net income $-147.9M · FCF $-91.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $1.46B | $1.46B | $1.50B | $1.27B | $1.05B | — | $491.1M | $145.5M |
| Net Income | $-147.9M | $-147.9M | $-135.8M | $-57.8M | $-270.1M | — | $-31.4M | $-42.0M |
| EBITDA | $-181.9M | $-181.9M | $-197.8M | $-81.1M | $-1.46B | — | $-27.8M | $-39.1M |
| EPS | -45.26 | -45.26 | -54.00 | -31.50 | -325.00 | — | — | — |
| Operating Margin | -18.5% | -18.5% | -20.8% | -13.3% | -23.4% | — | -5.8% | -27.2% |
| Net Margin | -10.1% | -10.1% | -9.1% | -4.6% | -25.7% | — | -6.4% | -28.8% |
| Balance Sheet | ||||||||
| Debt/Equity | -1.84 | -1.84 | 2.57 | 0.86 | 18.10 | 0.29 | — | — |
| Current Ratio | 0.24 | 0.24 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-91.2M | $-91.2M | $-110.1M | $-77.9M | $-128.3M | — | $-27.5M | $-29.7M |
| Returns | ||||||||
| ROE | 95.3% | 95.3% | -178.9% | -40.6% | -4614.4% | — | — | — |
| Valuation | ||||||||
| P/B | — | — | 0.48 | 2.67 | 11.80 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | -2.8% | -2.8% | 18.5% | 20.7% | — | — | 237.5% | — |
| EPS Growth | 16.2% | 16.2% | -71.4% | 90.3% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+71.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-54.00 → -45.26
Residual
+71.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.